<DOC>
	<DOC>NCT00907764</DOC>
	<brief_summary>Regadenoson is approved in the US under the brand name Lexiscan for myocardial perfusion imaging. This study will test whether regadenoson is an appropriate stress agent for stress echocardiography.</brief_summary>
	<brief_title>Stress Echocardiography Study With Regadenoson</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Regadenoson</mesh_term>
	<criteria>Patients with a clinically indicated dobutamine echocardiogram showing normal wall motion at rest and abnormal wall motion with stress Patients with a clinically indicated dipyridamole echocardiogram showing normal perfusion and wall motion at rest and abnormal perfusion with or without abnormal wall motion with stress Any condition precluding the safe administration of dobutamine, dipyridamole or SonoVue for echocardiography Pregnant or breastfeeding, or (if premenopausal), not practicing acceptable method of birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>